Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation

British Journal of Dermatology

Volumn 172, Issue 4, 2015, Pages 940-950

  Tembhre, M K ^a   Parihar, A S ^a   Sharma, V K ^a   Sharma, A ^a   Chattopadhyay, P ^a   Gupta, S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MACROPHAGE DERIVED CHEMOKINE; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ADULT; APOPTOSIS; ARTICLE; BODY SURFACE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITILIGO; CONFOCAL MICROSCOPY; IMMUNOLOGY; METABOLISM; SKIN;

ADULT; CHEMOKINE CCL21; CHEMOKINE CCL22; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MALE; MICROSCOPY, CONFOCAL; PROGRAMMED CELL DEATH 1 RECEPTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; VITILIGO;

EID: 84926185843     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13511     Document Type: Article

References (56)

1. Boissy RE, Manga P,. On the etiology of contact/occupational vitiligo. Pigment Cell Res 2004; 17: 208-14.
2. Cucchi ML, Frattini P, Santagostino G, Orecchia G,. Higher plasma catecholamine and metabolite levels in the early phase of non-segmental vitiligo. Pigment Cell Res 2000; 13: 28-32.
3. Lerner AB,. Vitiligo. J Invest Dermatol 1959; 32: 285-310.
4. Garbelli S, Mantovani S, Palermo B, Giachino C,. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? Pigment Cell Res 2005; 18: 234-42.
5. Ongenae K, Van Geel N, Naeyaert JM,. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
6. Schallreuter KU, Bahadoran P, Picardo M, et al,. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol 2008; 17: 139-40.
7. Van den Boorn JG, Konijnenberg D, Dellemijn TA, et al,. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129: 2220-32.
8. Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP,. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev 2007; 6: 138-42.
9. + T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis. Mol Med Rep 2013; 7: 237-41.
10. + cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 2012; 7: e37513.
11. Sakaguchi S,. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101: 455-8.
12. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52.
13. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN,. Regulatory T cells and human disease. Clin Dev Immunol 2007; 2007: 89195.
14. Hori S, Nomura T, Sakaguchi S,. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
15. Fontenot JD, Rudensky AY,. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6: 331-7.
16. Wildin RS, Freitas A,. IPEX and FOXP3: clinical and research perspectives. J Autoimmun 2005; 25 (Suppl.): 56-62.
17. Wildin RS, Smyk-Pearson S, Filipovich AH,. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002; 39: 537-45.
18. Paust S, Lu L, McCarty N, Cantor H,. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA 2004; 101: 10398-403.
19. Fallarino F, Grohmann U, Hwang KW, et al,. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4: 1206-12.
20. Taylor A, Verhagen J, Blaser K, et al,. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology 2006; 117: 433-42.
21. Levings MK, Bacchetta R, Schulz U, Roncarolo MG,. The role of IL-10 and TGF-β in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129: 263-76.
22. Tomura M, Honda T, Tanizaki H, et al,. Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest 2010; 120: 883-93.
23. + Tregs. Clin Immunol 2008; 126: 291-302.
24. + regulatory T cells bear functional skin-homing receptors. J Immunol 2006; 177: 4488-94.
25. Schneider MA, Meingassner JG, Lipp M, et al,. CCR7 is required for the in vivo function of CD4CD25 regulatory T cells. J Exp Med 2007; 204: 735-45.
26. Sather BD, Treuting P, Perdue N, et al,. Altering the distribution of Foxp3 regulatory T cells results in tissue-specific inflammatory disease. J Exp Med 2007; 204: 1335-47.
27. + ratio correlate with disease onset and progression in patients with generalized vitiligo. Pigment Cell Melanoma Res 2013; 26: 586-91.
28. Ben Ahmed M, Zaraa I, Rekik R, et al,. Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res 2012; 25: 99-109.
29. Klarquist J, Denman CJ, Hernandez C, et al,. Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 2010; 23: 276-86.
30. Agata Y, Kawasaki A, Nishimura H, et al,. Expression of the PD1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-72.
31. Ishida Y, Agata Y, Shibahara K, Honjo T,. Induced expression of PD1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-95.
32. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ,. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8: 239-45.
33. Keir ME, Butte MJ, Freeman GJ, Sharpe AH,. PD1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
34. Gotot J, Gottschalk C, Leopold S, et al,. Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc Natl Acad Sci USA 2012; 109: 10468-73.
35. Freeman GJ, Long AJ, Iwai Y, et al,. Engagement of the PD1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-34.
36. Latchman Y, Wood CR, Chernova T, et al,. PD-L2 is a second ligand for PD1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-8.
37. Francisco LM, Sage PT, Sharpe AH,. The PD1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-42.
38. Greenwald RJ, Latchman YE, Sharpe AH,. Negative co-receptors on lymphocytes. Curr Opin Immunol 2002; 14: 391-6.
39. + regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp 2003; 252: 67-88.
40. Gershon RK, Kondo K,. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970; 18: 723-35.
41. Basak PY, Adiloglu AK, Ceyhan AM, et al,. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 2009; 60: 256-60.
42. + T cells from patients with non-segmental vitiligo. Arch Dermatol Res 2011; 303: 685-9.
43. + T-cells in active and stable nonsegmental vitiligo. Int J Dermatol 2014; 53: 940-6.
44. Zhou L, Li K, Shi YL, et al,. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells. Pigment Cell Melanoma Res 2012; 25: 602-11.
45. Chatterjee S, Eby JM, Al-Khami AA, et al,. A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol 2014; 134: 1285-94.
46. Tembhre MK, Sharma VK, Sharma A, et al,. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo. Clin Chim Acta 2013; 424: 27-32.
47. Lim HW, Broxmeyer HE, Kim CH,. Regulation of trafficking receptor expression in human forkhead box P3 regulatory T cells. J Immunol 2006; 177: 840-51.
48. hi regulatory T cells in healthy males and females mediate gender difference in the prevalence of autoimmune diseases. Clin Lab 2012; 58: 567-71.
49. Keir ME, Francisco LM, Sharpe AH,. PD1 and its ligands in T-cell immunity. Curr Opin Immunol 2007; 19: 309-14.
50. + resting regulatory T cells from activated T cells. J Immunol 2006; 176: 2808-16.
51. Scott-Browne JP, Shafian S, Tucker-Heard G, et al,. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med 2007; 204: 2159-69.
52. Sharma MD, Sharma MD, Baban B, et al,. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 2570-82.
53. + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009; 119: 551-64.
54. Okazaki T, Honjo T,. PD1 and PD1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813-24.
55. Okazaki T, Chikuma S, Iwai Y, et al,. A rheostat for immune responses: the unique properties of PD1 and their advantages for clinical application. Nat Immunol 2013; 14: 1212-18.
56. Jin HT, Ahmed R, Okazaki T,. Role of PD1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011; 350: 17-37.